We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

GVYM:TASEGav-Yam Lands Corp. Ltd Analysis

Data as of 2026-03-12 - not real-time

ILA 3,648.00

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

The stock is trading just above its identified support at 3,608 and below the 20‑day SMA of 3,986, with a neutral trend and a 30‑day volatility of roughly 38%, suggesting a fragile short‑term footing. The RSI of 34 points to oversold conditions, yet the MACD remains bearish, and declining volume adds to the uncertainty. On the valuation side, the trailing P/E of 12 is well below the industry average of 32, indicating relative earnings attractiveness, but the price‑to‑book ratio of 164 is astronomically high, signaling a possible overvaluation relative to net assets. Dividend yield of 2.9% and a payout ratio under 45% provide some income cushion, but the debt‑to‑equity ratio above 150% raises concerns about financial leverage.
Fundamentally, revenue is growing at 16.6% with strong gross margins (≈84%) and positive free cash flow, supporting the dividend and operational stability. However, the massive debt load, modest ROE of 13.5%, and a beta near zero (minimal market correlation) combine to create a mixed risk profile. Given the technical oversold signals, solid dividend, but high leverage and extreme P/B, the outlook leans toward cautious positioning, favoring a hold in the near term and a more defensive stance over longer horizons.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • Price near support level
  • Oversold RSI but bearish MACD
  • Decreasing volume

Medium Term

1–3 years
Neutral
Model confidence: 6/10

Key Factors

  • Strong revenue growth and margins
  • Sustainable dividend yield
  • High leverage and elevated P/B ratio

Long Term

> 3 years
Cautious
Model confidence: 4/10

Key Factors

  • Debt‑to‑equity exceeding 150%
  • Price-to-book far above peers
  • Neutral trend with limited upside potential

Key Metrics & Analysis

Financial Health

Revenue Growth16.60%
Profit Margin72.26%
P/E Ratio12.0
ROE13.47%
ROA2.72%
Debt/Equity153.26
P/B Ratio163.9
Op. Cash FlowILA530.7M
Free Cash FlowILA177.8M
Industry P/E32.5

Technical Analysis

TrendNeutral
RSI34.8
SupportILA 3,608.00
ResistanceILA 4,490.00
MA 20ILA 3,986.05
MA 50ILA 4,049.28
MA 200ILA 3,693.82
MACDBearish
VolumeDecreasing
Fear & Greed Index74.07

Valuation

Target PriceILA 4,600.00
Upside/Downside26.10%
GradeOvervalued
TypeBlend
Dividend Yield2.88%

Risk Assessment

Beta-0.05
Volatility38.50%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.